What is enbosarm?

Enobosarm (also known as GTx-024 or S-22) is a nonsteroidal selective androgen receptor modulator (SARM) that has been developed as a potential treatment for muscle wasting and osteoporosis. It selectively binds to the androgen receptor in muscle and bone tissue, causing anabolic effects without the androgenic side effects seen with testosterone or other anabolic steroids.

Enobosarm has undergone several clinical trials, but its approval by the US Food and Drug Administration (FDA) has been delayed due to concerns about its safety and efficacy. In recent years, there have been reports of athletes and bodybuilders using enobosarm as a performance-enhancing drug, which has raised further concerns about its safety and legality.

Despite the controversy surrounding its use, enobosarm has shown promising results in improving muscle strength and lean body mass in clinical trials, particularly in cancer patients with cachexia (muscle wasting). However, more research is needed to fully understand its potential benefits and risks.